Mark Hensley
Fortuna: 84 767 $ al 31/07/2026
Fortuna: 84 767 $ al 31/07/2026
Mark E.
Hensley is currently Chairman at Calliditas Therapeutics AB and Chief Operating Officer & Executive Vice President at Heron Therapeutics, Inc. starting in 2025.
Formerly, Mr. Hensley was Chief Commercial Officer at Veloxis Pharmaceuticals A from 2018 to 2021.
Education includes an undergraduate degree from the University of North Texas.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
HERON THERAPEUTICS INC 0,09 % | 06/08/2026 | 170.901 ( 0,09 % ) | 84 767 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CALLIDITAS THERAPEUTICS AB | Presidente | - |
| HERON THERAPEUTICS, INC. | Director de Operaciones | 28/04/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| VELOXIS PHARMACEUTICALS A/S | Corporate Officer/Principal | 01/01/2021 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Heron Therapeutics, Inc.
Heron Therapeutics, Inc. BiotechnologyHealth Technology Manufactures and commercializes of polymer technologies | Health Technology |
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients | Health Technology |
University of North Texas
University of North Texas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Calliditas Therapeutics AB
Calliditas Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.